These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 18040685)

  • 1. MPL 515 and JAK2 mutation analysis in MDS presenting with a platelet count of more than 500 x 10(9)/l.
    Zipperer E; Wulfert M; Germing U; Haas R; Gattermann N
    Ann Hematol; 2008 May; 87(5):413-5. PubMed ID: 18040685
    [No Abstract]   [Full Text] [Related]  

  • 2. MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
    Steensma DP; Caudill JS; Pardanani A; McClure RF; Lasho TL; Tefferi A
    Haematologica; 2006 Dec; 91(12 Suppl):ECR57. PubMed ID: 17194663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation.
    Szpurka H; Gondek LP; Mohan SR; Hsi ED; Theil KS; Maciejewski JP
    Leukemia; 2009 Mar; 23(3):610-4. PubMed ID: 18818701
    [No Abstract]   [Full Text] [Related]  

  • 4. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
    Schmitt-Graeff AH; Teo SS; Olschewski M; Schaub F; Haxelmans S; Kirn A; Reinecke P; Germing U; Skoda RC
    Haematologica; 2008 Jan; 93(1):34-40. PubMed ID: 18166783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms.
    Patnaik MM; Lasho TL; Finke CM; Gangat N; Caramazza D; Siragusa S; Hanson CA; Pardanani A; Tefferi A
    Leukemia; 2010 Apr; 24(4):859-60. PubMed ID: 20111067
    [No Abstract]   [Full Text] [Related]  

  • 6. The JAK2 V617F mutation is rare in RARS but common in RARS-T.
    Ceesay MM; Lea NC; Ingram W; Westwood NB; Gäken J; Mohamedali A; Cervera J; Germing U; Gattermann N; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Nov; 20(11):2060-1. PubMed ID: 16932338
    [No Abstract]   [Full Text] [Related]  

  • 7. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms.
    Siemiatkowska A; Bieniaszewska M; Hellmann A; Limon J
    Leuk Res; 2010 Mar; 34(3):387-9. PubMed ID: 19643476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
    Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
    Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
    [No Abstract]   [Full Text] [Related]  

  • 9. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
    Patnaik MM; Tefferi A
    Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
    Guglielmelli P; Pancrazzi A; Bergamaschi G; Rosti V; Villani L; Antonioli E; Bosi A; Barosi G; Vannucchi AM; ;
    Br J Haematol; 2007 May; 137(3):244-7. PubMed ID: 17408465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis.
    Pardanani A; Lasho TL; Finke CM; Tefferi A
    Am J Hematol; 2011 Aug; 86(8):701-2. PubMed ID: 21674576
    [No Abstract]   [Full Text] [Related]  

  • 12. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MPL mutation profile in JAK2 mutation-negative patients with myeloproliferative disorders.
    Ma W; Zhang X; Wang X; Zhang Z; Yeh CH; Uyeji J; Albitar M
    Diagn Mol Pathol; 2011 Mar; 20(1):34-9. PubMed ID: 21326037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.
    Pardanani A; Guglielmelli P; Lasho TL; Pancrazzi A; Finke CM; Vannucchi AM; Tefferi A
    Leukemia; 2011 Dec; 25(12):1834-9. PubMed ID: 21691276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic/myeloproliferative disorders.
    Malcovati L; Cazzola M
    Haematologica; 2008 Jan; 93(1):4-6. PubMed ID: 18166777
    [No Abstract]   [Full Text] [Related]  

  • 16. Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.
    Gibson SE; Schade AE; Szpurka H; Bak B; Maciejewski JP; Hsi ED
    Hum Pathol; 2008 Jul; 39(7):1111-4. PubMed ID: 18479730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
    Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
    Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis.
    Schnittger S; Bacher U; Haferlach C; Dengler R; Kröber A; Kern W; Haferlach T
    Leukemia; 2008 Feb; 22(2):453-5. PubMed ID: 17713548
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevalence of the JAK2 V617F and MPL mutations in stroke, abdominal and peripheral venous thrombosis.
    McCarthy N; McCarron SL; Langabeer SE
    Acta Haematol; 2010; 124(3):160-1. PubMed ID: 20938171
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
    Atallah E; Nussenzveig R; Yin CC; Bueso-Ramos C; Tam C; Manshouri T; Pierce S; Kantarjian H; Verstovsek S
    Leukemia; 2008 Jun; 22(6):1295-8. PubMed ID: 18059483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.